Rankings
▼
Calendar
TNGX Q4 2020 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$9M
Gross Profit
$9M
95.3% margin
Operating Income
-$9M
-97.8% margin
Net Income
-$9M
-97.0% margin
EPS (Diluted)
$-0.42
QoQ Revenue Growth
+181.2%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$19M
Stock-Based Comp.
$531,000
Balance Sheet
Total Assets
$207M
Total Liabilities
$169M
Stockholders' Equity
$39M
Cash & Equivalents
$28M
← FY 2020
All Quarters
Q1 2021 →